Ultragenyx reported a quarterly loss of $1.84 per share, wider than the Zacks consensus estimate of a $1.55 loss and worse than the $1.57 loss in the same quarter last year. The results indicate a modest deterioration in profitability, with the EPS miss likely to weigh on shares. No revenue or guidance details were included in the article.
Ultragenyx reported a quarterly loss of $1.84 per share, wider than the Zacks consensus estimate of a $1.55 loss and worse than the $1.57 loss in the same quarter last year. The results indicate a modest deterioration in profitability, with the EPS miss likely to weigh on shares. No revenue or guidance details were included in the article.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.42
Ticker Sentiment
